Oric Pharmaceuticals (NASDAQ:ORIC) Shares Up 4.1% on Analyst Upgrade

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report)’s stock price shot up 4.1% on Tuesday after Citigroup raised their price target on the stock from $16.00 to $17.00. Citigroup currently has a buy rating on the stock. Oric Pharmaceuticals traded as high as $7.95 and last traded at $7.8280. Approximately 116,932 shares changed hands during trading, a decline of 93% from the average daily volume of 1,706,746 shares. The stock had previously closed at $7.52.

A number of other research firms also recently issued reports on ORIC. JPMorgan Chase & Co. raised their target price on Oric Pharmaceuticals from $23.00 to $26.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 14th. Wedbush dropped their price target on shares of Oric Pharmaceuticals from $17.00 to $14.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 27th. HC Wainwright raised their price objective on shares of Oric Pharmaceuticals from $25.00 to $27.00 and gave the stock a “buy” rating in a report on Monday, August 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research note on Thursday, October 15th. Finally, Wall Street Zen upgraded shares of Oric Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, July 25th. Fourteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Oric Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.33.

Read Our Latest Report on ORIC

Insider Transactions at Oric Pharmaceuticals

In other Oric Pharmaceuticals news, CFO Dominic Piscitelli sold 14,000 shares of Oric Pharmaceuticals stock in a transaction that occurred on Tuesday, October 20th. The shares were sold at an average price of $13.53, for a total transaction of $189,420.00. Following the completion of the sale, the chief financial officer directly owned 69,828 shares in the company, valued at $944,772.84. The trade was a 16.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 105,000 shares of company stock worth $1,432,952 in the last three months. Insiders own 5.70% of the company’s stock.

Institutional Trading of Oric Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Quarry LP boosted its stake in shares of Oric Pharmaceuticals by 23.9% in the 3rd quarter. Quarry LP now owns 20,848 shares of the company’s stock valued at $281,000 after purchasing an additional 4,018 shares in the last quarter. Bellevue Group AG purchased a new position in shares of Oric Pharmaceuticals in the third quarter worth about $75,000. Toronto Dominion Bank purchased a new position in shares of Oric Pharmaceuticals in the third quarter worth about $5,253,000. Entropy Technologies LP bought a new stake in shares of Oric Pharmaceuticals in the 3rd quarter valued at about $225,000. Finally, Jump Financial LLC lifted its stake in shares of Oric Pharmaceuticals by 39.3% in the 3rd quarter. Jump Financial LLC now owns 182,988 shares of the company’s stock valued at $2,465,000 after acquiring an additional 51,588 shares during the last quarter. Hedge funds and other institutional investors own 95.05% of the company’s stock.

Oric Pharmaceuticals Stock Performance

The company has a market cap of $797.07 million, a P/E ratio of -5.68 and a beta of 1.23. The business has a 50 day moving average price of $11.45 and a two-hundred day moving average price of $10.99.

Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report) last posted its quarterly earnings results on Monday, November 16th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.05). As a group, research analysts expect that Oric Pharmaceuticals, Inc. will post -1.53 EPS for the current year.

Oric Pharmaceuticals Company Profile

(Get Free Report)

Oric Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its research centers on therapies intended to address treatment resistance and improve outcomes for people with tumors that have become difficult to treat. The company’s drug candidates have included ORIC-114, a targeted therapy designed to inhibit EGFR and HER2 alterations, and ORIC-944, which targets the PRC2 pathway and has been investigated for prostate cancer. These programs are investigational and are not approved medicines.

Featured Stories

Receive News & Ratings for Oric Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oric Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.